购物车
- 全部删除
- 您的购物车当前为空
Sintilimab (IBI308) 是一种人源化的 IgG4 单克隆抗体,具有显著的抗肿瘤活性,通过与 PD-1 结合从而阻断 PD-1 与其配体 (PD-L1 和 PL-L2) 的相互作用,进而恢复内源性抗肿瘤 T 细胞反应。Sintilimab 联合其他化合物来治疗经典霍奇金淋巴瘤、非小细胞肺癌和食管癌。
为众多的药物研发团队赋能,
让新药发现更简单!
Sintilimab (IBI308) 是一种人源化的 IgG4 单克隆抗体,具有显著的抗肿瘤活性,通过与 PD-1 结合从而阻断 PD-1 与其配体 (PD-L1 和 PL-L2) 的相互作用,进而恢复内源性抗肿瘤 T 细胞反应。Sintilimab 联合其他化合物来治疗经典霍奇金淋巴瘤、非小细胞肺癌和食管癌。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,660 | 现货 | |
5 mg | ¥ 4,320 | 现货 | |
10 mg | ¥ 7,360 | 现货 | |
25 mg | ¥ 10,900 | 现货 | |
50 mg | ¥ 14,700 | 现货 |
产品描述 | Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer. |
别名 | Sintilimab (anti-PD-1), IBI308 |
分子量 | 144.04 kDa |
CAS No. | 2072873-06-2 |
存储 | store at low temperature | store at -20°C | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容